$Amazing $Biotech & $olid $Microcap $tocks

[ash111]

ONCS beside next week SITC presentation,Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC (TNBC).
Estimated Study Completion Date:June 2018
Estimated Primary Completion Date:December 2017 (Final data collection date for primary outcome measure
https://clinicaltrials.gov/ct2/show/NCT02531425?term=oncosec&rank=2

Trial of pIL-12/MK-3475 in Metastatic Melanoma
Primary Completion Date:March 2018 
https://clinicaltrials.gov/ct2/show/NCT02493361?term=pIL-12&rank=3

Excellent results so far and 3 new stakes past week (about 20% of O/S). MC is a total joke relating Market Potential and company well positioned, safe holding thru Mid-2018 and beyond:
https://www.prnewswire.com/news-releases/oncosec-presents-positive-phase-2-data-for-immunopulse-il-12-in-combination-with-pembrolizumab-demonstrating-a-best-overall-response-rate-borr-of-50-in-predicted-anti-pd-1-non-responder-melanoma-patients-300539506.html

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold.  $5.67’s average target is 339.53% above currents $1.29 stock price.
https://bzweekly.com/it-seems-oncosec-medical-nasdaqoncs-will-go-up-just-reported-less-shorted-shares/